DiaMedica Therapeutics Inc. is a biopharmaceutical company. It engages in the development of novel recombinant proteins and monoclonal antibodies. The companys lead product principally consists DM199, a recombinant human tissue kallikrein-1 protein. It operates primarily in the United States and Canada. DiaMedica Therapeutics Inc. is headquartered in Minneapolis, Minnesota.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-24.44M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.29 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -61.35% |
| Return on Assets (Trailing 12 Months) | -55.53% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.02 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.02 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.79 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.18 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.60 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.64 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 42.88M |
| Free Float | 39.75M |
| Market Capitalization | $179.68M |
| Average Volume (Last 20 Days) | 0.10M |
| Beta (Past 60 Months) | 1.29 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 10.12% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |